ClinicalTrials.gg

Program

AZD0292

A development code.

Its studies are mostly in Bronchiectasis, led by AstraZeneca.

Furthest: phase 2, since Jul 17, 20254 company-led studies, 2 open or runningNext primary completion: Dec 9, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca42 open or runningphase 2since Jul 17, 2025Mar 8, 2024Dec 9, 2027phase 2 · NCT07088926
  • Named in AstraZeneca’s own pipeline as AZD0292, phase 2, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2024First study: phase 1 study in Healthy Participants StudyFirst studyNCT06311760 · 32 enrolled · United States
  2. Jul 17, 2025Phase 2 study in Bronchiectasis With Pseudomonas Aeruginosa ColonizationNCT07088926 · 435 planned · United States, Argentina, Australia and more
  3. Oct 28, 2025Phase 1 study in Healthy ParticipantsNCT07222254 · 18 enrolled · Japan
  4. Jun 24, 2026Phase 2 study in Bronchiectasis With Pseudomonas Aeruginosa ColonizationNCT07774403 · 84 planned · China

Ahead

  1. Dec 9, 2027Primary completion: phase 2 study in Bronchiectasis With Pseudomonas Aeruginosa ColonizationNCT07088926
  2. Jan 18, 2028Primary completion: phase 2 study in Bronchiectasis With Pseudomonas Aeruginosa ColonizationNCT07774403

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.”study summary, read by Claude · the study

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07774403Bronchiectasis With Pseudomonas Aeruginosa Colonization · China2RecruitingJan 18, 202884
NCT07222254Healthy Participants · Japan1CompletedJul 30, 202618
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization · United States, Argentina, Australia and more2RecruitingDec 9, 2027435
NCT06311760Healthy Participants Study · United States1CompletedFeb 20, 202532

How it is read

Names in the registry

  • “AZD0292”, 4 entries

Codes read as this program: AZD0292.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.